Effect of supplementation in treatment of gestational diabetes

Effect of omega-3 supplementation on inflammatory factors, biomarkers of oxidative stress and pregnancy outcomes in gestational diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201406305623N20

Enrollment

Registered

2014-07-16

Start date

2014-05-10

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes. Diabetes mellitus in pregnancy, unspecified

Interventions

Intervention 1: Intervention group: Omega-3 pearl, 1000 mg, daily, for 6 weeks orally. Intervention 2: Control group: Placebo pearl, daily, for 6 weeks orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Pregnant women aged 18-40 years diagnosed with GDM at 24-28 weeks' gestation

Exclusion criteria

Exclusion criteria: Pre-existing diabetes Required complex diets Chronic medical conditions Significant psychiatric disease Smokers Kidney or liver diseases Chronic hypertension Hypothyroidism

Design outcomes

Primary

Measure	Time frame
Infants' weight. Timepoint: Delivery time. Method of measurement: Scale.;Infants' head circumference. Timepoint: Delivery time. Method of measurement: Tape.;Newborns' length. Timepoint: Delivery time. Method of measurement: Tape.;Polyhydramnios. Timepoint: After the intervention. Method of measurement: Sonography.;Newborn's bilirubin. Timepoint: Delivery time. Method of measurement: Enzymatic kit.;Apgar score. Timepoint: Delivery time. Method of measurement: Clinical observation.;Preterm delivery. Timepoint: After delivery. Method of measurement: Medical record.;Maternal pre-eclampsia. Timepoint: After delivery. Method of measurement: Medical record.;Maternal hospitalization. Timepoint: After delivery. Method of measurement: Medical record.	—

Measure

Time frame

Infants' weight. Timepoint: Delivery time. Method of measurement: Scale.;Infants' head circumference. Timepoint: Delivery time. Method of measurement: Tape.;Newborns' length. Timepoint: Delivery time. Method of measurement: Tape.;Polyhydramnios. Timepoint: After the intervention. Method of measurement: Sonography.;Newborn's bilirubin. Timepoint: Delivery time. Method of measurement: Enzymatic kit.;Apgar score. Timepoint: Delivery time. Method of measurement: Clinical observation.;Preterm delivery. Timepoint: After delivery. Method of measurement: Medical record.;Maternal pre-eclampsia. Timepoint: After delivery. Method of measurement: Medical record.;Maternal hospitalization. Timepoint: After delivery. Method of measurement: Medical record.

—

Secondary

Measure	Time frame
Hs-CRP. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: ELISA kit.;Nitric oxide. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Hs-CRP. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: ELISA kit.;Nitric oxide. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026